IDEAYA Reaches FDA Agreement On Late-Stage Trial Plan For Lung Cancer Drug, Plans Phase 3 Lung Cancer Study For IDE849 By Year-End 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3
IDEAYA got the okay from the FDA to test a new lung cancer drug in a big, late-stage study starting by the end of 2026. This means the company's plan is on track, but we won't know if the drug actually works until the study is done.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.